What is CNBX Pharms's earnings per share (EPS)?

CNBX Pharms (CNBX) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CNBX Pharms (CNBX) Financials

CNBX

FY2025 annual

Revenue $0 -100.0% YoY

Net Income Not reported for FY2025

EPS (Diluted) $0.00 YoY not available

Free Cash Flow Not reported for FY2025

Market Cap $161K as of Sep 9, 2026

Price / Sales n/m revenue is not positive, FY2025

Price / Earnings n/m no net income reported

Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended May 31, 2026 Reported Jun 24, 2026 Currency USD FYE August

Newest figures come from the 10-Q for Q3 FY2026, filed Jun 24, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CNBX SEC filings page.

CNBX Pharms (CNBX) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CNBX FY2025 2026-09-05

Development-stage operations remain disconnected from receipts, while financing pressure dominates the balance sheet.

In FY2023, operating cash flow was -$113K against an operating loss of -$931K, while R&D spending reached $432K; the gap indicates that reported losses included substantial non-cash or timing effects beyond immediate cash usage.

Liabilities of $2.5M were roughly five times total assets, leaving the company with negative equity. A 0.1x current ratio shows that near-term obligations greatly exceed current assets, making the balance sheet’s financing structure more important than margin analysis.

Some figures from recent filings were inconsistent and were omitted from this summary.

Financial Health Signals

Financial health score not available

CNBX Pharms does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

CNBX Pharms generated $0 in revenue in Q3 2026.

EPS (Diluted)

$0.00

CNBX Pharms earned $0.00 per diluted share (EPS) in Q3 2026.

EBITDA

Not reported for Q3 2026.

Net Income

Not reported for Q3 2026.

Cash & Balance Sheet

Cash & Debt

$9K

YoY-30.5%

QoQ-21.9%

5Y CAGR-65.6%

10Y CAGR-20.0%

CNBX Pharms held $9K in cash as of Q3 2026; long-term debt is not reported for that period.

Shares Outstanding

1.61B

QoQ+31.0%

5Y CAGR+61.4%

CNBX Pharms had 1.61B shares outstanding in Q3 2026. Against the prior quarter it is up 31.0%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

None of these metrics is reported for Q3 2026.

Capital Allocation

None of these metrics is reported for Q3 2026.

CNBX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CNBX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	N/A	$0-100.0%	$130K-68.3%	$410K+1269.1%	$30K	$0-100.0%	$7K-27.3%	$10K+2.5%	$10K+68.9%	$6K-94.9%	$113K	$0	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$6K-94.9%	$113K	$0	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$0-100.0%	$195K-54.9%	$432K-63.5%	$1.2M-33.2%	$1.8M+5.3%	$1.7M+9.0%	$1.5M+53.8%	$1.0M+306.5%	$247K+39.0%	$178K+27.4%	$139K	$0	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	$518K-43.0%	$910K-49.5%	$1.8M+117.3%	$829K-36.7%	$1.3M-11.7%	$1.5M-38.1%	$2.4M+80.5%	$1.3M+517.5%	$215K	N/A	$40K+40335.0%	$100+122.2%	$45	N/A
Operating Income	N/A	N/A	-$583K+37.4%	-$931K+68.5%	-$3.0M-13.6%	-$2.6M+14.6%	-$3.0M+7.9%	-$3.3M+13.3%	-$3.8M-105.4%	-$1.9M-560.5%	-$281K	N/A	-$216K-271.9%	-$58K	N/A	N/A
EBITDA	N/A	N/A	-$511K+33.6%	-$769K+72.1%	-$2.8M-15.8%	-$2.4M+15.9%	-$2.8M+9.2%	-$3.1M+16.3%	-$3.7M-101.4%	-$1.8M-561.7%	-$279K	N/A	-$216K-271.8%	-$58K	N/A	N/A
Interest Expense	N/A	$40K+106.1%	$19K+1545.5%	$1K-7.8%	$1K-46.8%	$2K-70.6%	$8K-55.7%	$18K+2053.5%	$852-80.5%	$4K-39.1%	$7K+137.2%	$3K+211.6%	$971+442.5%	$179+1276.9%	$13	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0	$0	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	-$3.7M-16.6%	-$3.2M+57.2%	-$7.5M-759.1%	$1.1M+130.0%	-$3.8M-95.3%	-$1.9M-529.5%	-$307K	N/A	-$270K-378.7%	-$56K-3314.1%	-$2K+98.5%	-$107K
EPS (Basic)	N/A	$0.00+100.0%	-$0.02+95.2%	-$0.42+88.3%	-$3.59-17850.0%	-$0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	$0.00	-$0.02+95.2%	-$0.42+88.3%	-$3.59	-$0.02	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	91M	30M+242.8%	9M+621.8%	1M	139M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Revenue	$0	$0	$0	N/A	$0	$0-100.0%	$0-100.0%	N/A
Cost of Revenue	$0	$0	N/A	N/A	$0	$0-100.0%	N/A	N/A
Gross Profit	$0	$0	N/A	N/A	$0	$0-100.0%	N/A	N/A
R&D Expenses	N/A	$0	$0	N/A	$0-100.0%	$0-100.0%	$0-100.0%	N/A
SG&A Expenses	N/A	$73K+12.7%	N/A	N/A	$40K-63.1%	$65K-51.6%	$37K-75.3%	N/A
Operating Income	N/A	-$73K-12.7%	N/A	N/A	-$40K+73.5%	-$65K+68.6%	-$37K+78.6%	N/A
EBITDA	N/A	N/A	N/A	N/A	-$40K+73.5%	-$65K+62.7%	-$37K+72.2%	N/A
Interest Expense	N/A	N/A	$46K+1382.9%	N/A	N/A	N/A	$3K-72.7%	N/A
Net Income	N/A	-$44K+36.8%	N/A	N/A	-$60K+54.3%	-$70K+78.6%	-$34K+80.8%	N/A
EPS (Basic)	$0.00	$0.00	$0.00+100.0%	$0.00	$0.00	$0.00+100.0%	$0.00+83.3%	$0.00-100.0%
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00+83.3%	$0.00-100.0%
Diluted Shares (Avg)	1.32B	931M	733M	N/A	43M	32M	31M+12.1%	N/A

Not reported in any period shown, so not listed: Income Tax.

CNBX Balance Sheet

CNBX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$18K-41.3%	$31K-93.7%	$499K-38.5%	$811K-73.7%	$3.1M+38.7%	$2.2M-85.4%	$15.2M+376.7%	$3.2M-12.4%	$3.6M+15238.8%	$24K-17.4%	$29K-74.9%	$114K+57.0%	$73K	N/A	N/A
Current Assets	$18K-41.3%	$31K-86.0%	$224K+13.1%	$198K-87.5%	$1.6M+71.1%	$930K-78.4%	$4.3M+165.7%	$1.6M-53.9%	$3.5M+15820.8%	$22K-13.4%	$26K-77.4%	$113K+55.0%	$73K	N/A	N/A
Cash & Equivalents	$15K-42.8%	$26K-79.6%	$130K+10.4%	$118K-91.5%	$1.4M+78.3%	$778K+192.4%	$266K-80.9%	$1.4M0.0%	$1.4M+7186.1%	$19K-24.2%	$25K-74.5%	$99K	$0	$0	$0
Short-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$3.3M	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0-100.0%	$6.0M+919.3%	$590K	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.5M+0.1%	$2.5M-0.2%	$2.5M+406.4%	-$821K-164.5%	$1.3M+179.9%	$455K+3.6%	$439K-18.6%	$539K-91.8%	$6.6M+1238.9%	$491K+45.2%	$338K+356.3%	$74K-58.4%	$178K	N/A	N/A
Current Liabilities	$2.5M+0.1%	$2.5M-0.2%	$2.5M+3.0%	$2.4M+91.9%	$1.3M+179.9%	$455K+3.6%	$439K-18.6%	$539K-22.8%	$699K+42.3%	$491K+45.2%	$338K+356.3%	$74K-58.4%	$178K+263.6%	$49K+3.5%	$47K
Non-Current Liabilities	$0	$0	$0+100.0%	-$3.3M	$0	$0	$0	$0-100.0%	$5.9M	$0	$0	$0	$0	N/A	N/A
Total Equity	-$2.5M-0.7%	-$2.5M-22.9%	-$2.0M-223.6%	$1.6M-9.6%	$1.8M+2.3%	$1.8M-88.0%	$14.7M+457.3%	$2.6M+190.0%	-$2.9M-528.7%	-$467K-51.0%	-$310K-872.5%	$40K+138.0%	-$105K-115.1%	-$49K-3.5%	-$47K
Retained Earnings	-$25.3M-1.3%	-$25.0M-2.9%	-$24.3M-18.1%	-$20.5M-22.1%	-$16.8M-23.4%	-$13.6M-121.2%	-$6.2M+15.5%	-$7.3M-107.3%	-$3.5M-121.9%	-$1.6M-24.0%	-$1.3M-73.4%	-$738K-57.7%	-$468K-13.7%	-$411K-0.4%	-$410K

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Total Assets	$13K-31.3%	$15K-70.6%	$11K-50.0%	$18K-41.3%	$19K-76.7%	$51K-69.1%	$22K-94.2%	$31K-93.7%
Current Assets	$13K-31.3%	$15K-70.6%	$11K-50.0%	$18K-41.3%	$19K-76.7%	$51K-69.1%	$22K-85.2%	$31K-86.0%
Cash & Equivalents	$9K-30.5%	$12K-73.4%	$8K-55.6%	$15K-42.8%	$14K-81.4%	$46K+23.0%	$17K-78.8%	$26K-79.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.7M+4.6%	$2.5M-2.8%	$2.6M+1.9%	$2.5M+0.1%	$2.6M+0.9%	$2.6M+3.9%	$2.5M+2.2%	$2.5M-0.2%
Current Liabilities	$2.7M+4.6%	$2.5M-2.8%	$2.6M+1.9%	$2.5M+0.1%	$2.6M+0.9%	$2.6M+3.9%	$2.5M+2.2%	$2.5M-0.2%
Non-Current Liabilities	$0	$0	$0	$0	$0	$0	$0	$0
Total Equity	-$2.7M-4.8%	-$2.5M+1.4%	-$2.6M-2.3%	-$2.5M-0.7%	-$2.5M-3.4%	-$2.6M-9.0%	-$2.5M-20.0%	-$2.5M-22.9%
Retained Earnings	-$25.6M-1.8%	-$25.4M-1.5%	-$25.4M-1.6%	-$25.3M-1.3%	-$25.1M-0.9%	-$25.1M-1.2%	-$25.0M-2.3%	-$25.0M-2.9%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CNBX Cash Flow Statement

CNBX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$154K	N/A	-$244K-117.1%	-$113K+93.3%	-$1.7M+32.6%	-$2.5M+10.2%	-$2.8M+10.3%	-$3.1M-56.7%	-$2.0M-128.7%	-$864K-619.0%	-$120K	N/A	-$195K-617.3%	-$27K	N/A	N/A
Depreciation & Amortization	N/A	$0-100.0%	$72K-55.4%	$162K-18.4%	$199K-10.1%	$221K+2.7%	$215K+13.9%	$189K+113.6%	$88K+1160.0%	$7K+345.1%	$2K+20.9%	$1K+1416.3%	$86	$0	N/A	N/A
Stock-Based Compensation	N/A	$0-100.0%	$140K-22.6%	$180K-75.2%	$729K	$0-100.0%	$72K-70.8%	$247K-86.7%	$1.9M+110.5%	$881K+2850.7%	$30K	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	$0-100.0%	$113K+359.4%	$25K-2.1%	$25K-96.1%	$645K-80.4%	$3.3M+162.6%	-$5.3M-264.1%	-$1.4M-1046.8%	-$126K	$0	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$150K	N/A	$28K-72.5%	$100K-74.3%	$390K-84.1%	$2.5M	$0-100.0%	$7.2M+400.2%	$1.4M-66.7%	$4.3M+3705.2%	$114K	N/A	N/A	$100K	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Operating Cash Flow	-$48K+8.4%	-$31K+40.9%	-$47K-21.3%	-$29K+40.8%	-$52K-23219.6%	-$52K+58.5%	-$39K+45.6%	-$48K-335.2%
Depreciation & Amortization	N/A	N/A	$0	$0	$0	$0-100.0%	$0-100.0%	$0-100.0%
Stock-Based Compensation	N/A	N/A	$0	N/A	N/A	N/A	$0-100.0%	N/A
Investing Cash Flow	N/A	N/A	$0	$0	$0-100.0%	$0-100.0%	$0+100.0%	$0
Financing Cash Flow	$45K+125.1%	$35K-56.3%	$40K+33.3%	$30K+2281.6%	$20K+1487.9%	$80K	$30K+20.0%	$1K-98.1%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

CNBX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CNBX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	100.0%0.0pp	100.0%	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-448.3%	-227.1%	-9860.4%	N/A	-42524.1%	-33563.0%	-39670.1%	-32616.1%	-249.5%	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	-12428.2%	N/A	-104337.9%	11510.4%	-39335.7%	-34022.5%	-273.1%	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	-228.1%-51.2pp	-176.9%+246.3pp	-423.2%-430.9pp	7.7%+150.4pp	-142.8%	N/A	N/A	N/A	-673.6%	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	-459.0%-355.3pp	-103.8%+232.7pp	-336.5%-343.9pp	7.5%+126.0pp	-118.6%-65.4pp	-53.2%+1242.1pp	-1295.3%	N/A	-236.4%-158.9pp	-77.5%	N/A	N/A
Current Ratio	0.010.0x	0.01-0.1x	0.090.0x	0.08-1.2x	1.25-0.8x	2.04-7.8x	9.81+6.8x	3.00-2.0x	5.03+5.0x	0.040.0x	0.08-1.4x	1.52+1.1x	0.41	N/A	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	0.70+0.4x	0.26+0.2x	0.03-0.2x	0.20	N/A	N/A	N/A	1.85	N/A	N/A	N/A
Asset Turnover	0.00-4.1x	4.14+3.3x	0.82+0.8x	0.040.0x	0.000.0x	0.000.0x	0.000.0x	0.000.0x	0.00-4.7x	4.74+4.7x	0.00	N/A	N/A	N/A	N/A

Metric	Q3'2610-Q	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K
Return on Assets	N/A	-296.0%-158.2pp	N/A	N/A	-320.8%-157.6pp	-137.8%+60.8pp	-154.0%-107.9pp	N/A
Current Ratio	0.000.0x	0.010.0x	0.000.0x	0.010.0x	0.010.0x	0.020.0x	0.01-0.1x	0.01-0.1x
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	N/A	0.000.0x	0.00-0.2x	0.00-0.2x	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
CNBX Pharms CNBX	FY2025	$0	N/A	N/A	$161K	—
PaxMedica, Inc. PXMD	FY2023	$0	-$18.3M	N/A	$2.8M	—
Marizyme MRZM	FY2023	$646K	-$69.5M	N/A	$40K	—

Where CNBX Pharms Ranks

Frequently Asked Questions

What is CNBX Pharms's annual revenue?

CNBX Pharms (CNBX) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is CNBX Pharms's revenue growing?

CNBX Pharms (CNBX) revenue declined by 100.0% year-over-year, from $130K to $0 in fiscal year 2025.

What are CNBX Pharms's total assets?

CNBX Pharms (CNBX) had $18K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does CNBX Pharms have outstanding?

CNBX Pharms (CNBX) had 554M shares outstanding as of fiscal year 2025.

What is CNBX Pharms's current ratio?

CNBX Pharms (CNBX) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is CNBX Pharms's P/E ratio?

CNBX Pharms (CNBX) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $161K as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is CNBX Pharms's price-to-sales ratio?

CNBX Pharms (CNBX) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $161K as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Why is CNBX Pharms's debt-to-equity ratio negative or not reported?

CNBX Pharms (CNBX) has negative shareholder equity of -$2.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.